Follow-up time began at randomisation and continued until date of death or until 31 December 2009, whichever came first.
For the determination of incident rates, the calculation of person-years began on the day of final hospital discharge for the index burn admission, and the study observation period continued until date of the defined cancer diagnosis, death or 31 December 2008, whichever occurred first.
Using information from the Cancer Registry and CPR, all individuals in the study population were followed through 31 December 2002 for any first primary diagnosis of cancer from 1 January 1989 or age 16 years, whichever occurred later, and continued until date of cancer diagnosis (except nonmelanoma skin cancer), death, emigration from North Jutland, or 31 December 2002, whichever came first.
Follow-up for NHL started on the date of enrollment at one of the study clinics (baseline) and continued until date of diagnosis of any cancer (except nonmelanoma skin cancer), date of death, date of emigration, or 31 July 2008 (end of follow-up), whichever came first.
Follow-up continued until the date of diagnosis, date of death, study end date (31 December 1998), or last known date before loss to follow-up, whichever was earliest.
Follow-up for each subject began on the date of questionnaire return and continued until the date of cancer diagnosis, date of censoring due to loss to follow-up, death or 31 December 2006, whichever came first.
Follow-up started on the date of the first IBS-related hospital contact and continued until the date of a colorectal cancer diagnosis, the date of another cancer diagnosis, the date of death, the date of migration, or 31 December 2008, whichever came first.
Follow-up time began at the date of randomisation and continued until the date of cancer diagnosis, death, or 31 December 2009, whichever came first.
Follow-up of each cohort member continued until the date of cancer diagnosis, the date of the last LSUHCSD encounter if the patient stopped using LSUHCSD hospitals, death, or 31 May 2012.
Follow-up to identify cases of NHL continued until the date of an NHL diagnosis, the date of a cancer diagnosis other than NHL (except nonmelanoma skin cancer), the date of a reimbursed prescription for non-HRT sex hormones, the date of death, the date of migration, or 31 December 2002, whichever came first.
Follow-up of each cohort member continued until the date of the diagnosis of LEA, the date of the last visit if the subject stopped use of LSUHCSD hospitals, death, or 31 May 2012.
